CSIMarket
 
Elanco Animal Health Inc  (ELAN)
Other Ticker:  
 
 
Price: $15.7200 $-0.03 -0.190%
Day's High: $15.86 Week Perf: -1.87 %
Day's Low: $ 15.53 30 Day Perf: -2.12 %
Volume (M): 3,601 52 Wk High: $ 16.88
Volume (M$): $ 56,611 52 Wk Avg: $11.68
Open: $15.66 52 Wk Low: $7.88



 Market Capitalization (Millions $) 7,741
 Shares Outstanding (Millions) 492
 Employees 6,550
 Revenues (TTM) (Millions $) 4,417
 Net Income (TTM) (Millions $) -1,231
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 178

Elanco Animal Health Inc
Elanco Animal Health Inc. is a global animal health company headquartered in Greenfield, Indiana, in the United States. The company develops, produces, and markets innovative products for animal health, including veterinary drugs, vaccines, feed additives, and other products for animal health and productivity. Elanco provides animal health products to farmers, pet owners, and veterinarians worldwide.

Elanco was founded in 1954 as a division of Eli Lilly and Company, a pharmaceutical company. In 2018, Elanco was spun off from Eli Lilly and Company to become a standalone company. Elanco has more than 6,000 employees and operates in more than 90 countries worldwide.

Elanco offers a wide range of animal health products for various species, including cattle, swine, poultry, fish, pets, and other companion animals. The company's products are built on innovative technologies that help improve animal health, welfare, and productivity.

Elanco's product portfolio includes antibiotics, parasiticides, vaccines, anticoccidials, enzymes, and other feed additives. The company has a strong presence in global markets, particularly in North America, Europe, and Asia Pacific.

In addition to its commercial products, Elanco is committed to developing sustainable solutions to address the challenges facing the animal farming industry. The company invests in research and development of new products and solutions that promote animal welfare and sustainability.

Elanco has a strong commitment to corporate social responsibility and sustainability. The company focuses on improving animal welfare, protecting the environment, and engaging in social responsibility initiatives in the communities where it operates. Elanco is a member of the United Nations Global Compact, a voluntary initiative that promotes sustainable and socially responsible business practices.

Overall, Elanco has a strong reputation in the animal health industry as a leading provider of innovative and effective animal health products. The company's commitment to sustainability and corporate social responsibility has earned it recognition as a responsible and ethical corporate citizen.


   Company Address: 2500 INNOVATION WAY GREENFIELD 46140 IN
   Company Phone Number: 352-6261   Stock Exchange / Ticker: NYSE ELAN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Personnel Announcements

Elanco Animal Health Appoints Shiv O'Neill as General Counsel and Corporate Secretary, Strengthening Global Operations

Published Mon, Mar 4 2024 1:33 PM UTC



Elanco Animal Health, a prominent global animal health company, has made a strategic move to enhance its leadership team. On March 4, 2024, Elanco announced the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel, and Corporate Secretary. This decision aims to strengthen Elanco's global strategy and operations, signaling the compa...

Elanco Animal Health Inc

Elanco Animal Health Inc Faces Deficit Despite Revenue Growth in Fiscal Fourth Quarter 2023



The recent financial results of Elanco Animal Health Inc for the fiscal fourth quarter of 2023 have caught the attention of investors and industry experts alike. The company's performance, unlike its peers in the Major Pharmaceutical Preparations industry, saw a substantial improvement in revenue growth and earnings per share. Furthermore, amidst concerns about methane emissions from livestock, Elanco Animal Health has partnered with Athian, a leading technology company, to develop innovative solutions that address this environmental challenge. This article interprets the financial results and explores the potential implications for Elanco Animal Health going forward.
Revenue Growth and Earnings:
In the fiscal fourth quarter of 2023, Elanco Animal Health witnessed a remarkable 5.505% increase in revenue, reaching $1.04 billion compared to $981.00 million in the same period a year ago. This growth is particularly noteworthy when contrasted with the Major Pharmaceutical Preparations industry, which experienced a significant decline of -15.67% in business. Moreover, earnings per share improved from $-2.22 per share in the previous reporting period, indicating a positive trajectory for the company. Although a quarterly deficit of -$0.28 per share was recorded, it is important to note that this represents an improvement compared to -$0.11 per share a year ago.

Contract

Harnessing Innovation: Athian and Elanco Animal Health Accelerate Sustainable Food Production through Methane Reduction

Published Thu, Nov 2 2023 11:16 AM UTC



In a groundbreaking partnership, Athian, a leading technology company, and Elanco Animal Health have joined forces to tackle one of the biggest challenges in the agriculture industry - methane emissions from livestock. The collaboration aims to transform food production by reducing enteric methane emissions and improving feed utilization through the use of innovati...

Elanco Animal Health Inc

Elanco Animal Health Inc Sees Increased Losses and Revenue Decline in Second Quarter of 2023

Elanco Animal Health Inc Faces Challenges as Fiscal Performance Declines
Elanco Animal Health Inc, a prominent player in the animal health industry, recently reported its fiscal performance for the period between April and June 2023. The results painted a challenging picture for the company, indicating a significant decrease in revenue and a larger-than-expected net shortfall.
Comparing this quarter's performance to the same period last year, Elanco reported a shortfall per share of $-0.20, a notable increase from $-0.04. Additionally, earnings per share fell from $0.21 in the previous reporting season. The revenue also took a hit, declining by -10.195% to $1.06 billion from $1.18 billion in the corresponding period last year. Furthermore, sequentially, the revenue fell by -15.911% from $1.26 billion.

Elanco Animal Health Inc

Elanco Animal Health Inc Surpasses Expectations with Strong Profit Margin Growth in Fiscal Q1 of 20232.

Investors in the stock market will be pleased to hear that Elanco Animal Health Inc has delivered impressive income growth on slow revenue advance in the financial period closing Mar 31 2023. With EPS grown rapidly by 110% at $0.21 per share and revenue rising slightly by 2.612% to $1.26 billion from the corresponding reporting season a year ago, Elanco Animal Health Inc has shown solid improvement in their financial standing.
Comparing the current reporting season to the previous one, we see an impressive turnaround as EPS turned positive from $-0.11 per share and revenue improved by 28.135% from $981.00 million. This significant growth is a testament to the hard work and dedication of the company and its employees. Furthermore, with net earnings of $103.000 million in the fiscal first quarter of 2023, up by 114.58% from the fiscal first quarter of 2023 a year ago, Elanco Animal Health Inc has shown remarkable strength in the face of challenging market conditions.






 

Elanco Animal Health Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Elanco Animal Health Inc does not provide revenue guidance.

Earnings Outlook
Elanco Animal Health Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com